Orin Green Financial LLC Invests $271,000 in Eli Lilly and Company (NYSE:LLY)

Orin Green Financial LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 306 shares of the company’s stock, valued at approximately $271,000.

Other large investors have also recently modified their holdings of the company. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $32,000. LGT Financial Advisors LLC purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $36,000. Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth about $40,000. Morton Brown Family Wealth LLC increased its holdings in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC increased its holdings in shares of Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after buying an additional 16 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.7 %

Shares of LLY traded up $6.41 during mid-day trading on Thursday, reaching $922.83. The company had a trading volume of 458,889 shares, compared to its average volume of 2,979,211. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm has a 50-day moving average price of $919.25 and a 200 day moving average price of $855.84. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a market capitalization of $877.06 billion, a price-to-earnings ratio of 136.51, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. On average, sell-side analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Truist Financial raised their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Bank of America raised their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday. They issued an “outperform” rating and a $1,100.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $986.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.